Eupraxia Pharmaceuticals Reports Fourth Quarter Results

March 23 (Reuters) - Eupraxia Pharmaceuticals Inc : * EUPRAXIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND 2022 FINANCIAL RESULTS * EUPRAXIA PHARMACEUTICALS INC - BELIEVES ITS CURRENT CASH IS

Lucy Scientific Discovery Announces Partnership With High Times® To Develop And Distribute A New Line Of Psychoactive Products

March 23 (Reuters) - Lucy Scientific Discovery Inc : * LUCY SCIENTIFIC DISCOVERY ANNOUNCES PARTNERSHIP WITH HIGH TIMES® TO DEVELOP AND DISTRIBUTE A NEW LINE OF PSYCHOACTIVE PRODUCTS Source text for

ADVISORY-Incorrect alerts on Aeterna Zentaris Q4 results‍ withdrawn

March 23 (Reuters) - Alerts on Aeterna Zentaris's Q4 results have been withdrawn as they were incorrectly published from a Palisade Bio press release, an unrelated company. For correct alerts on

Immunoprecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing A Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated With Poor Prognosis And Survival Rates

March 23 (Reuters) - Immunoprecise Antibodies Ltd : * IMMUNOPRECISE PRESENTS NOVEL T-CELL ENGAGING BISPECIFIC ANTIBODIES ADDRESSING A UNIQUE ONCOLOGICAL TARGET, TROPOMYOSIN RECEPTOR KINASE B,

Knight Therapeutics Reports Fourth Quarter And Year-End 2022 Results

March 23 (Reuters) - Knight Therapeutics Inc: * KNIGHT THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2022 RESULTS * FOR FISCAL 2023, EXPECTS TO REPORT $280 TO $300 MILLION IN REVENUE * QTRLY LOSS

Charlotte's Web Reports 2022 Fourth Quarter And Year-End Financial Results

March 23 (Reuters) - Charlotte's Web Holdings Inc : * CHARLOTTE'S WEB REPORTS 2022 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS * CHARLOTTE'S WEB HOLDINGS INC Q4 LOSS PER SHARE $0.23 * CHARLOTTE'S

Fsd Pharma Announces Its Australian Entity Receives Approval To Proceed With Phase 1 Clinical Trial Of Lucid-201, A Candidate For The Potential Treatment Of Major Depressive Disorder

March 22 (Reuters) - FSD Pharma Inc: * FSD PHARMA ANNOUNCES ITS AUSTRALIAN ENTITY RECEIVES APPROVAL TO PROCEED WITH PHASE 1 CLINICAL TRIAL OF LUCID-201, A CANDIDATE FOR THE POTENTIAL TREATMENT OF

Medexus Announces New License Deal For Topical Terbinafine

March 22 (Reuters) - Medexus Pharmaceuticals Inc : * MEDEXUS ANNOUNCES NEW LICENSE DEAL FOR TOPICAL TERBINAFINE * MEDEXUS PHARMACEUTICALS INC - SECURED CANADIAN RIGHTS TO COMMERCIALIZE TERBINAFINE

Aptose Biosciences Inc <APTO.O>: A loss of 11 cents per share anticipated for fourth quarter

21 March 2023 09:21 p.m. All figures in US dollars. Aptose Biosciences Inc is expected to show an increase in its fourth quarter earnings to -11 cents​ per share according to the mean Refinitiv

Aptose Biosciences Inc expected to post a loss of 11 cents a share - Earnings Preview

* Aptose Biosciences Inc is expected to show no change in quarterly revenue when it reports results on March 23. * * ​Refinitiv's mean analyst estimate for Aptose Biosciences Inc is for a loss of 11